☆ 4.3 Article

The valley of death: why Australia failed to develop clinically effective drugs in COVID-19

INTERNAL MEDICINE JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Review Biology

Treating COVID-19: Targeting the Host Response, Not the Virus

David S. S. Fedson

Summary: In low- and middle-income countries, inexpensive generic drugs, such as statins, ACE inhibitors, and ARBs, may be the only practical way to save severe COVID-19 patients' lives. These drugs target the host response to infection and are already available in all countries. Observational studies have shown that statin treatment reduces mortality, but randomized controlled trials have not confirmed this. Combination therapy has been tested for antivirals and dexamethasone, but not for inexpensive generic drugs. Future research should include testing combination generic drug treatments for use in low- and middle-income countries.

LIFE-BASEL (2023)

Add to Collection

Review Respiratory System

Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis

Guiling Zhou et al.

Summary: This study systematically evaluated published studies on repurposed drugs for the prevention of SARS-CoV-2 infection and/or COVID-19 among healthy adults. The evidence on the effectiveness of these drugs for prophylaxis is inconclusive, indicating a need for further research to determine feasible prevention strategies.

BMJ OPEN RESPIRATORY RESEARCH (2023)

Add to Collection

Review Pharmacology & Pharmacy

Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment

Richard J. Head et al.

Summary: This article discusses the importance of viewing the COVID-19 pandemic from a systems analysis perspective and highlights the thermodynamic basis of SARS-CoV-2 infection. By combining pharmacology and human physiology, the study reveals the key mechanisms of SARS-CoV-2 infection and emphasizes the impact of viral surface structure variations on immune evasion and infectivity.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)

Add to Collection

Review Pharmacology & Pharmacy

The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment

Eugenie R. Lumbers et al.

Summary: Interaction between SARS-CoV-2 and its receptor ACE2 leads to an uncontrolled inflammatory response, resulting in the pathogenesis of COVID-19. The renin-angiotensin system plays a crucial role in the host response to infection and injury, and disruption of ACE2 by SARS-CoV-2 leads to tissue damage.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)

Add to Collection

Letter Nutrition & Dietetics

Obesity and COVID-19: renin-angiotensin as a mediator of morbidity and mortality

Jennifer H. Martin et al.

BRITISH JOURNAL OF NUTRITION (2022)

Add to Collection

Review Pharmacology & Pharmacy

A practical treatment for COVID-19 and the next pandemic

Jahar Bhattacharya et al.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension

Sonali R. Gnanenthiran et al.

Summary: This meta-analysis suggests that the use of RASi in adults with COVID-19 does not increase all-cause mortality, slightly decreases the risk of acute myocardial infarction, but increases the risk of acute kidney injury.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Add to Collection

Review Pharmacology & Pharmacy

A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19

Jennifer H. Martin et al.

Summary: The lack of a clear therapeutic framework for COVID-19 has led to the adoption of potentially unsafe treatments; focusing on host treatment and repurposing drugs based on historical data are crucial for developing effective treatments against the virus.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Review Health Care Sciences & Services

COVID-19, host response treatment, and the need for political leadership

David S. Fedson

Summary: Health officials and scientists are warning of a potentially devastating influenza pandemic, but we are currently facing the global coronavirus (COVID-19) pandemic. To effectively treat patients, using inexpensive and widely available drugs targeting the host response rather than the virus itself could be a promising approach.

JOURNAL OF PUBLIC HEALTH POLICY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial

Marie W. Munch et al.

Summary: In patients with COVID-19 and severe hypoxemia, the use of 12 mg/d of dexamethasone compared to 6 mg/d did not lead to a statistically significant difference in the number of days alive without life support at 28 days. The study may have lacked the power to detect a significant effect.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

News Item Multidisciplinary Sciences

HOW COVID BROKE THE EVIDENCE PIPELINE

Helen Pearson

Summary: The pandemic has stress-tested the world's way of producing evidence and brought to light all the flaws.

NATURE (2021)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Did our pharmacological strategy for COVID-19 fail?

Jennifer H. Martin et al.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)

Add to Collection

Article Medicine, General & Internal

Steroid harms if given early in COVID-19 viraemia

Kanupriya Arora et al.

Summary: COVID-19 is a biphasic illness, with immune regulation being key to treatment, and early preventive medication may worsen the condition.

BMJ CASE REPORTS (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Optimizing the Trade-off Between Learning and Doing in a Pandemic

Derek C. Angus

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Chloroquine and hydroxychloroquine in covid-19

Robin E. Ferner et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Letter Pharmacology & Pharmacy

Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses

Craig R. Rayner et al.

ANTIVIRAL RESEARCH (2020)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Buying time: Drug repurposing to treat the host in COVID-19H

Jennifer H. Martin et al.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19

Huseyin Naci et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.